LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSanidad

20.28 3.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.33

Máximo

20.54

Métricas clave
By Trading Economics
Ingresos	11M -61M
Ventas	7.9M 46M
BPA	-0.7
Margen de beneficios	-132.36
Empleados	270
EBITDA	6.3M -58M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+89.97% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	532M 1.7B
Apertura anterior	17.18
Cierre anterior	20.28

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

318 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 dic 2025, 21:08 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms Buys AI-Device Maker Limitless

5 dic 2025, 19:39 UTC

Principales Movimientos del Mercado

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dic 2025, 19:17 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 dic 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dic 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

5 dic 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dic 2025, 21:36 UTC

Charlas de Mercado

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dic 2025, 21:12 UTC

Charlas de Mercado

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dic 2025, 21:03 UTC

Charlas de Mercado

Ganancias

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dic 2025, 21:01 UTC

Charlas de Mercado

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dic 2025, 20:43 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dic 2025, 20:43 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dic 2025, 20:42 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dic 2025, 20:01 UTC

Adquisiciones, fusiones, absorciones

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dic 2025, 19:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 dic 2025, 19:44 UTC

Charlas de Mercado

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dic 2025, 19:39 UTC

Charlas de Mercado

Silver Climbs to a New Record High -- Market Talk

5 dic 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:30 UTC

Charlas de Mercado

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dic 2025, 18:28 UTC

Adquisiciones, fusiones, absorciones

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:24 UTC

Adquisiciones, fusiones, absorciones

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dic 2025, 18:20 UTC

Charlas de Mercado

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dic 2025, 18:11 UTC

Charlas de Mercado

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dic 2025, 17:48 UTC

Charlas de Mercado

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dic 2025, 17:44 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

5 dic 2025, 17:44 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Correction to Imax Market Talk

5 dic 2025, 17:35 UTC

Charlas de Mercado

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 dic 2025, 17:25 UTC

Charlas de Mercado

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

89.97% repunte

Estimación a 12 Meses

Media 37.5 USD 89.97%

Máximo 56 USD

Mínimo 24 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

318 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.